Last reviewed · How we verify
Elizaria®
Elizaria is a small molecule that targets the S1P1 receptor.
Elizaria is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | Elizaria® |
|---|---|
| Also known as | Eculizumab, eculizumab |
| Sponsor | AO GENERIUM |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Biologic |
| Therapeutic area | Multiple Sclerosis |
| Phase | Phase 3 |
Mechanism of action
By binding to the S1P1 receptor, Elizaria modulates the sphingosine-1-phosphate (S1P) signaling pathway, which plays a crucial role in immune cell trafficking and lymphocyte egress from lymphoid organs.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®
- Observational Study of Elizaria® in aHUS Patients
- Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elizaria® CI brief — competitive landscape report
- Elizaria® updates RSS · CI watch RSS
- AO GENERIUM portfolio CI